Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Minneapolis, Minnesota 55455


Everolimus is an immunosuppressive drug that is being studied for preventing acute rejection that can happen after heart transplantation. It is usually used in combination with other immunosuppressive drugs such as cyclosporine. The purpose of this study is to evaluate the change in kidney function after beginning everolimus, while determining the most effective Neoral® (cyclosporine) dose to take with everolimus, in adult cardiac transplant patients who have had their transplanted heart for at least 1 year and who have cardiac allograft vasculopathy.


Inclusion Criteria: - Male or female adult with an established cardiac allograft vasculopathy defined as any new luminal irregularity on coronary angiography. - Patient must be on statins at study entry. - Patient who is more than 12 months post-transplant. Exclusion Criteria: - Patient with a serum creatinine value >2.0 mg/dL. - Patient with a biopsy-proven acute rejection episode (>= ISHLT 3A) within 6 months prior to study entry. - Patient who had received any investigational drug within 4 weeks prior to study entry.



Primary Contact:

Study Director
Richard Dorent, MD
Novartis Pharmaceuticals

Backup Contact:


Location Contact:

Minneapolis, Minnesota 55455
United States

There is no listed contact information for this specific location.

Site Status: N/A

Data Source: ClinicalTrials.gov

Date Processed: January 21, 2020

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.